Clinical Trial Search

Primary: Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo — 8.8; 10.7 mL/min — p=0.756

Primary: Successful Device Placement — 10 participants

Primary: Serum Cidal Activity as Tested Against Staphylococcus Aureus Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 2; 4; 1; 1 Log inhibition

Primary: Hepatic Fat — 4.7; 6.5 percent of liver fat

Primary: Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) — 27; 28 participants

Primary: Incidence of Biopsy-confirmed Acute Rejection by Banff '97 Criteria (Updated 2007) 3, 6 and 12 Months Post Transplant — 7; 3; 7; 3 participants

Primary: Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine — 30.1; 32.0; 232; 225 Titers (1/dilutions)

Primary: Thrombin Generation Test: Baseline — 1810; 1682 nM*minutes

Primary: Change From Baseline in the Mean 24-Hour Systolic Blood Pressure (SBP) to Week 6 — 136.7; 136.5; 139.6; -1.26 millimeter of mercury (mmHg) — p=0.062

Primary: Efficacy of the Treatment Assessed With Visual Acuity Measured by ETDRS Charts. — 0.18; 0.36; 0.18 logMAR

Primary: Change in Triglycerides From Baseline to 16 Weeks — -54.13 mg/dL

Primary: Percentage of Participants With Hemostasis at the IMA — 100.0 percentage of subjects

Primary: Change in HIV RNA (Copies/Million Rectal Cells) — 1.1; -0.2 copies/million rectal cells — p=0.63

Primary: Bone Mineral Density — -1.3; -1.1 z-score

Primary: The 17-item Hamilton Rating Scale for Depression (HRSD17) — 9.18; 9.41 units on a scale — p=0.9084